AngioDynamics (ANGO) announced the publication of results from the PRESERVE study in the journal European Urology. The study assessed the safety and effectiveness of irreversible electroporation with the NanoKnife System to ablate prostate tissue in patients with intermediate-risk prostate cancer. The study met its primary effectiveness endpoint, with 84% of men free from in-field, clinically significant disease at 12 months.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANGO:
- AngioDynamics’ Strong FY25 Performance and Optimistic FY26 Outlook Support Buy Rating
- AngioDynamics initiated with a Buy at Lake Street
- AngioDynamics price target raised to $17 from $15 at Canaccord
- AngioDynamics Reports Strong Growth in Fiscal 2025
- AngioDynamics Reports Strong Growth Amid Challenges